Eagle Bioscience’s Human Ceruloplasmin ELISA Assay Kit was utilized in a recent study! The study sought to learn about the impact of sacubitril/valsartan on cardiac and systemic hypoxia in those with chronic heart failure. Check out the abstract and full text below!


In heart failure patients with reduced ejection fraction, Sacubitril/valsartan(S/V) increased proBNPT71 glycosylation, which is regulated negatively by hypoxia via miR-30a in-vitro. Using a cohort of 73 HFrEF patients who were transitioned from standard HF medication to S/V, we found that the increase in proBNP T71 glycosylation after S/V was associated with a decrease in cardiac hypoxia. We further found that plasma levels of K709-acteylatedHIF1a, HIF-regulated and HIF-independent biomarkers also evolved consistently with a decrease in hypoxia. We further confirmed that biomarker changes were related to hypoxia, in a rat model subjected to isobaric hypoxia. We measured them in rats subjected to isobaric hypoxia. Overall, these data strongly suggest that optimally treated HFrEF patients exhibited sub clinical hypoxia that is improved by S/V. The data also posit proBNP T71 glycosylation as a biomarker of cardiac hypoxia.

Nougué, Picard, Cohen-Solal et al. Impact of sacubitril/valsartan on cardiac and systemic hypoxia in chronic heart failure. iScience (2024) 27 (1), 108520 DOI: 10.1016/j.isci.2023.108520

If you have any questions about the Human Ceruloplasmin ELISA Assay Kit or any of our other offerings, contact us here.